These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 25773740)

  • 21. Do PCSK9 inhibitors reduce cardiovascular events?
    Kolber MR; Nickonchuk T; Turgeon R
    Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099
    [No Abstract]   [Full Text] [Related]  

  • 22. Lack of evidence for recommended low-density lipoprotein cholesterol treatment targets.
    Modest GA
    Ann Intern Med; 2007 Apr; 146(8):614; author reply 614-5. PubMed ID: 17438326
    [No Abstract]   [Full Text] [Related]  

  • 23. [Considerable LDL lowering is advantageous].
    MMW Fortschr Med; 2005 Sep; 147(35-36):9. PubMed ID: 16180563
    [No Abstract]   [Full Text] [Related]  

  • 24. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 25. Drugs for lipids.
    Treat Guidel Med Lett; 2011 Mar; 9(103):13-20. PubMed ID: 21350395
    [No Abstract]   [Full Text] [Related]  

  • 26. [Statins remain the standard. New methods for lipid lowering therapy].
    Aumiller J
    MMW Fortschr Med; 2001 Oct; 143(42):16-7. PubMed ID: 11697281
    [No Abstract]   [Full Text] [Related]  

  • 27. Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease.
    Stein EA
    Mayo Clin Proc; 2009 Apr; 84(4):307-9. PubMed ID: 19339646
    [No Abstract]   [Full Text] [Related]  

  • 28. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary.
    Mooradian AD
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):598; author reply 602. PubMed ID: 16094774
    [No Abstract]   [Full Text] [Related]  

  • 29. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 30. Stricter cholesterol guidelines broaden indications for the 'statin' drugs.
    Capriotti T
    Medsurg Nurs; 2003 Feb; 12(1):51-7. PubMed ID: 12619600
    [No Abstract]   [Full Text] [Related]  

  • 31. Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?
    Aronow WS
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):591-2. PubMed ID: 15972605
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
    Sabatine MS; Giugliano RP; Wiviott SD; Raal FJ; Blom DJ; Robinson J; Ballantyne CM; Somaratne R; Legg J; Wasserman SM; Scott R; Koren MJ; Stein EA;
    N Engl J Med; 2015 Apr; 372(16):1500-9. PubMed ID: 25773607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Inhibitors of PCSK9].
    Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
    Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Significant decline in the rate of cardiovascular incidents].
    Wedekind S
    MMW Fortschr Med; 2015 Jun; 157(11):66. PubMed ID: 26049360
    [No Abstract]   [Full Text] [Related]  

  • 35. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
    Lüscher TF
    Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743
    [No Abstract]   [Full Text] [Related]  

  • 36. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Cholesterol and the aged: ...and the beat goes on.
    Wilson MM
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):600-2; author reply 602. PubMed ID: 15972610
    [No Abstract]   [Full Text] [Related]  

  • 37. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary.
    Levy DR; Pearson TA
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):597-8; author reply 602. PubMed ID: 16094772
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aronow's "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Aim low.
    Nash IS
    J Gerontol A Biol Sci Med Sci; 2005 May; 60(5):599-600; author reply 602. PubMed ID: 15972609
    [No Abstract]   [Full Text] [Related]  

  • 40. Maximum Low-density Lipoprotein Cholesterol Lowering Capacity Achievable With Drug Combinations. When 50 Plus 20 Equals 60.
    Masana L; Ibarretxe D; Plana N
    Rev Esp Cardiol (Engl Ed); 2016 Mar; 69(3):342-3. PubMed ID: 26856792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.